linagliptin and semaglutide together Is it safe to combine (a DPP‑4 inhibitor) with (a GLP‑1 receptor agonist) in a patient with type 2 diabetes who is already taking empagliflozin (an SGLT2 inhibitor)? Targeting GLP-1, GIP & GCG

The 7.2 mg dose was approved to help patients achieve deeper weight reductionproducing nearly 20% total weight loss in the STEP UP clinical trialsputting its efficacy much closer to that of tirzepatide

And the consequence of this and were wrestling with this right now is that a larger study is needed to investigate this association, but without a diagnostic code, it is very difficult to appreciate how were going to find those cases

I told her that was a horrible idea for that very reason

Using 2mL gives you 2.5mg/mL concentration (20 IU = 0.5mg), while 2.5mL gives 2mg/mL (25 IU = 0.5mg)

3,4 This is why GLP-1 RAs were initially studied exclusively for diabetes management